![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Immune thrombocytopenia (ITP) is a common autoimmune hematological disorder. Despite this, diagnosis is still challenging due to clinical heterogeneity and the lack of a specific diagnostic test. New findings in the pathology and the availability of new drugs have led to the development of different guidelines worldwide. In the present study, the Delphi methodology has been used to get a consensus on the management of adult patients with ITP in Spain and to help in decision-making. The Delphi questionnaire has been designed by a scientific ad hoc committee and has been divided into 13 topics, with a total of 127 items, covering the maximum possible scenarios for the management of ITP. As a result of the study, a total consensus of 81% has been reached. It is concluded that this Delphi consensus provides practical recommendations on topics related to diagnosis and management of ITP patients to help doctors to improve outcomes. Some aspects remain unclear, without consensus among the experts. Thus, more advances are needed to optimize ITP management.
Plain Language Summary
What is the context?
Immune thrombocytopenia (ITP) is a hematologic autoimmune disease characterized by accelerated destruction and inadequate production of platelets mediated by autoantibodies (platelet count <100 × 109 /L).
Despite being a common condition, its heterogeneous clinical course makes its diagnosis and management still a challenge.
In recent years, new molecules with different mechanisms of action have emerged for the treatment of ITP.
Due to the increasing information about the pathology and its therapies, several international guidelines have recently been established to provide recommendations for the management and treatment of ITP.
There are still many patient scenarios and disease aspects which are not addressed in the guidelines.
What is new?
Our Spanish ITP Expert Group has developed a Delphi consensus study to provide recommendations and promote standardization of the management of adult patients with ITP in Spain.
The scientific committee defined 127 statements for consensus, corresponding to 13 chapters: (i) Diagnosis of ITP, (ii) First-line treatment, (iii) Second-line treatment, (iv) Treatment of refractory patients, (v) Follow-up, (vi) Emergency and surgery, (vii) ITP in the elderly, (viii) ITP in pregnancy, (ix) Anticoagulation and antiplatelet, (x) Secondary ITP, (xi) Quality of life, (xii) Discontinuation of TPO-RA, and (xiii) ITP and Covid.
The total number of agreed statements achieved was 103, giving a final percentage of consensus in the Delphi questionnaire of 81%.
What is the impact?
This Delphi consensus provides recommendations based on real clinical practice data, regarding the diagnosis, treatment, and management of patients and scenarios in ITP to assist clinicians in addressing this disease and achieving optimal outcomes for the patient.
Acknowledgments
The authors would like to thank Luzán 5 Health Consulting for their support with the Delphi methodology, and Estefanía Hurtado Gómez for the medical writing.
Disclosure statement
Tomás José González-López has received research grants from Sobi, Grifols, Amgen, and Novartis and speaker honoraria from Sobi, Grifols, Amgen, Novartis, Momenta, Alpine, and Argenx. Isidro Jarque reports consulting honorarium from Amgen, Novartis, and Shionogi. Rest of authors declare no competing financial interests.
Author contributions
All authors contributed significantly to the study presented. All authors have read and approved the article.
Original manuscript statement
This manuscript has not been published in any language or has been submitted to any other journal at the same time.
Supplementary material
Supplemental data for this article can be accessed online at https://doi.org/10.1080/09537104.2024.2336104.